Lord Hunt of Kings Heath

The Care Quality Commission (CQC) has not instructed or advised Healthwatch England to refrain from public comment about its abolition or the transfer of its functions.

The CQC is operationally independent and continues to work with Healthwatch England in line with its statutory duties.

The Department continues to engage with both the CQC and Healthwatch England, as its strategic functions move to a new patient experience directorate within the Department following Dr Penny Dash’s Review of patient safety across the health and care landscape.

Ambulance paramedics are regulated by the Health and Care Professions Council (HCPC), but the HCPC does not set a national list of procedures such as catheterisation or infusion. Paramedics are highly trained and competent professionals who may routinely and autonomously carry out procedures such as cannulation in the field.

However, while waiting for hospital admission, whether paramedics are able to undertake or supervise these procedures depends on a number of factors, such as local policies and clinical governance frameworks.

The Government expects all system partners to work together to provide robust protection measures, including handover protocols, to ensure patients are cared for in the right place, at the right time.

It was not expected that all trusts would adopt the platform by April 2026, and the NHS Federated Data (NHS FDP) programme is on track to support adoption of the NHS FDP to 85% of all National Health Service trusts by March 2026.

NHS England published its regular benefits and uptake data on 12 February 2026, which shows that at the end of January 2026 there were 110 NHS trusts live or in delivery of the Federated Data Platform. 167 trusts have signed up to the NHS FDP, or 81% of the 205 providers of secondary and tertiary care in the NHS.

It was not expected that all trusts would adopt the platform by April 2026, and the NHS Federated Data (NHS FDP) programme is on track to support adoption of the NHS FDP to 85% of all National Health Service trusts by March 2026.

NHS England published its regular benefits and uptake data on 12 February 2026, which shows that at the end of January 2026 there were 110 NHS trusts live or in delivery of the Federated Data Platform. 167 trusts have signed up to the NHS FDP, or 81% of the 205 providers of secondary and tertiary care in the NHS.

Healthwatch has played an important role in supporting patient involvement in the National Health Service, and in our 10-Year Health Plan we recognise the valuable work they have done to gather patient feedback and influence the debate around local service delivery.

Healthwatch was one of six organisations covered by Dr Penny Dash’s review of patient safety across the health and care landscape. The review found that there are too many organisations doing this type of work, which can create confusion for patients and risks limiting impact given their distance from service providers and commissioners.

In response, we have committed in our 10-Year Health Plan to bring Healthwatch England’s strategic functions ‘in house’ within a reformed Department, giving patients a stronger national voice through the creation of a new National Director of Patient Experience. At the same time, the statutory functions of Local Healthwatch will be brought together with the involvement and engagement responsibilities of integrated care boards, ensuring that patient insight is more directly connected to local decision-making and service improvement.

In 2020, NHS England commissioned placenta accreta networks in the United Kingdom which support local and regional screening, shared protocols, and co-ordinated referral pathways to specialist pregnancy accreta centres. These centres consist of highly experienced multidisciplinary teams with the expertise to manage this condition and improve the safety outcomes for women and babies.

At present, placenta accreta spectrum is not included as an indicator in NHS England maternity safety improvement programmes and dashboards. There are no plans to add this as an indicator in the future.

There are no plans to introduce mandatory national reporting of placenta accreta spectrum cases and outcomes. Neither Mothers and Babies: Reducing Risk through Audits and Confidential Enquiries across the UK (MBRRACE-UK) nor the National Maternity and Perinatal Audit record placenta accreta spectrum routinely in regular surveillance. However, MBRRACE-UK captures this data as part of the haemorrhage confidential enquiries. There are currently no plans to discuss the publication of this data.

There are currently no plans to introduce mandatory national reporting of placenta accreta spectrum cases and outcomes. Neither Mothers and Babies: Reducing Risk through Audits and Confidential Enquiries across the UK (MBRRACE-UK) nor the National Maternity and Perinatal Audit record placenta accreta routinely in regular surveillance. However, MBRRACE-UK captures this data as part of their confidential enquiries relating to haemorrhage.

In 2020, NHS England commissioned placenta accreta networks in the United Kingdom which support local and regional screening, shared protocols, and co-ordinated referral pathways to specialist pregnancy accreta centres. Placenta accreta centres consist of highly experienced multidisciplinary teams with the expertise to manage this condition and improve the safety outcomes for women and babies.

There are currently no plans to introduce mandatory national reporting of placenta accreta spectrum cases and outcomes. Neither Mothers and Babies: Reducing Risk through Audits and Confidential Enquiries across the UK (MBRRACE-UK) nor the National Maternity and Perinatal Audit record placenta accreta routinely in regular surveillance. However, MBRRACE-UK captures this data as part of their confidential enquiries relating to haemorrhage.

In 2020, NHS England commissioned placenta accreta networks in the United Kingdom which support local and regional screening, shared protocols, and co-ordinated referral pathways to specialist pregnancy accreta centres. Placenta accreta centres consist of highly experienced multidisciplinary teams with the expertise to manage this condition and improve the safety outcomes for women and babies.

In 2020, NHS England commissioned placenta accreta networks in the United Kingdom which support local and regional screening, shared protocols, and co-ordinated referral pathways to specialist pregnancy accreta centres. These centres consist of highly experienced multidisciplinary teams with the expertise to manage this condition and improve the safety outcomes for women and babies.

At present, placenta accreta spectrum is not included as an indicator in NHS England maternity safety improvement programmes and dashboards. There are no plans to add this as an indicator in the future.

There are no plans to introduce mandatory national reporting of placenta accreta spectrum cases and outcomes. Neither Mothers and Babies: Reducing Risk through Audits and Confidential Enquiries across the UK (MBRRACE-UK) nor the National Maternity and Perinatal Audit record placenta accreta spectrum routinely in regular surveillance. However, MBRRACE-UK captures this data as part of the haemorrhage confidential enquiries. There are currently no plans to discuss the publication of this data.

In 2020, NHS England commissioned placenta accreta networks in the United Kingdom which support local and regional screening, shared protocols, and co-ordinated referral pathways to specialist pregnancy accreta centres. These centres consist of highly experienced multidisciplinary teams with the expertise to manage this condition and improve the safety outcomes for women and babies.

At present, placenta accreta spectrum is not included as an indicator in NHS England maternity safety improvement programmes and dashboards. There are no plans to add this as an indicator in the future.

There are no plans to introduce mandatory national reporting of placenta accreta spectrum cases and outcomes. Neither Mothers and Babies: Reducing Risk through Audits and Confidential Enquiries across the UK (MBRRACE-UK) nor the National Maternity and Perinatal Audit record placenta accreta spectrum routinely in regular surveillance. However, MBRRACE-UK captures this data as part of the haemorrhage confidential enquiries. There are currently no plans to discuss the publication of this data.

NHS England is responsible for determining allocations of financial resources to integrated care boards (ICBs), informed by a target formula to determine the ‘fair share’ of total funding available for each ICB. NHS England published allocations for ICBs covering 2026/27 to 2028/29 in November 2025, with further information available at the following link:

https://www.england.nhs.uk/publication/allocation-of-resources-2026-27-to-2027-28/

Our Medium-Term Planning Framework, published in October 2025, made it clear to integrated care boards (ICBs) that timely and effective community health services will be critical to shifting care out of hospital and into the community to deliver our ambitions for neighbourhood health.

ICB core programme allocations for 2026/27 to 2028/29, published in November 2025, gave an average recurrent allocation growth across all ICBs in England of 2.72% in 2026/27 and 2.92% in 2027/28.

And, for the first time, we have set a target for systems to reduce long waits for community health services in the Medium-Term Planning Framework. By 2028/29 at least 80% of community health services activity should take place within 18 weeks, bringing community health services in line with targets for elective care. Systems have also been asked to increase the capacity of community health services and to work to standardise the provision of core community services.

To help bring about integration, the Department and NHS England will create effective mechanisms which enable service level funding to flow from acute care to community health services and create financial incentives to invest in services that improve patient outcomes and deliver better value by creating funding flows and payment mechanisms that connect the savings from improved quality of care with the investment in new services in the community.

We remain committed to working together across Government and with national autism charities to improve services and outcomes for autistic people.

On 23 January, we published our response to the House of Lords Autism Act 2009 Inquiry Committee’s report Time to deliver: The Autism Act 2009 and the new autism strategy. We are carefully considering the report’s recommendations as well as our approach to the national autism strategy and will set out a position, including our plans to engage with stakeholders, in due course.

The Autism Act 2009 places a duty on my Rt Hon. Friend, the Secretary of State for Health and Social Care, to consult on, publish, and keep under review a national strategy for meeting the needs of autistic adults in England. My Rt Hon. Friend may choose to revise the strategy, and if so, must publish it as revised.

On 23 January 2026, we published our response to the House of Lords Autism Act 2009 Inquiry Committee’s report Time to deliver: The Autism Act 2009 and the new autism strategy. We are carefully considering the report’s recommendations, as well as our approach to developing a new national autism strategy and will set out a position in due course. The current strategy will remain in effect until a revised strategy is published.

The 10-Year Health Plan sets out to make the National Health Service fit for the future, by delivering three big shifts, from hospital to care in community, from analogue to digital, and from sickness to prevention. The plan will help to address health inequalities for disabled and autistic people by improving access to care, delivering care closer to home, and supporting the development of holistic care plans for those whose needs may require support from multiple health and care providers. We want autistic people’s access to, and experience of, healthcare services to be equitable, effective, and responsive to their needs.

The plan sets out the core principle of early intervention and support, including without the need for diagnosis, including specifically for children and young people, such as those with special educational needs and disabilities (SEND). It is clear about the importance of health services working in partnership with education settings and providing children and young people with early intervention and support to avoid needs escalating, where possible, building on learning from programmes such as Early Language Support for Every Child. We will set out our proposals for SEND reform in the upcoming Schools White Paper.

NHS England continues to support local systems to use a national framework and operational guidance to deliver improved outcomes in all-age autism assessment pathways. It has published national guidance on meeting the needs of autistic adults in mental health services and, to address physical health inequalities, is currently testing a combined health check in primary care for autistic people, those with a severe mental health condition and/or those people with a learning disability.

The Government recognises the importance of ensuring that the National Health Service workforce is provided with high-quality training to support them to deliver quality care to patients living with obesity.

The curricula for postgraduate specialty training are developed by royal colleges and faculties and approved by the General Medical Council. Standards of education and proficiency are the responsibility of the statutorily independent professional regulators.

Individual employers are responsible for appropriate ongoing training and continuing professional development to ensure they continue to provide safe and effective care. NHS England and other organisations support employers and the NHS workforce by providing and signposting to evidence‑based training resources on weight management. These include programmes that incorporate behavioural approaches, and in some cases psychological elements, available through platforms such as e‑Learning for Healthcare, the Royal College of General Practitioners Obesity Hub, and the Strategic Centre for Obesity Professional Education programme.

The Government recognises the importance of ensuring that the National Health Service workforce is provided with high-quality training to support them to deliver quality care to patients living with obesity.

The curricula for postgraduate specialty training are developed by royal colleges and faculties and approved by the General Medical Council. Standards of education and proficiency are the responsibility of the statutorily independent professional regulators.

Individual employers are responsible for appropriate ongoing training and continuing professional development to ensure they continue to provide safe and effective care. NHS England and other organisations support employers and the NHS workforce by providing and signposting to evidence‑based training resources on weight management. These include programmes that incorporate behavioural approaches, and in some cases psychological elements, available through platforms such as e‑Learning for Healthcare, the Royal College of General Practitioners Obesity Hub, and the Strategic Centre for Obesity Professional Education programme.

The National Health Service and local government provide a range of obesity services, from universal prevention initiatives to targeted interventions, including behaviour change programmes, digital tools and apps, and specialist services for people living with severe obesity and related conditions. These services support individuals at every stage to achieve and maintain a healthier weight.

Commissioning and funding decisions for obesity services are made locally by local authorities and NHS organisations in line with assessed population needs and available budgets. The Department works with these partners and NHS England to provide national policy direction, to support effective and sustainable service models and to introduce digital behavioural programmes.

NHS England is supporting integrated care boards (ICBs) to deliver a phased roll‑out of tirzepatide for the treatment of obesity. They have provided funding and guidance to ICBs and established a national wraparound support service for patients receiving these treatments, covering diet, physical activity, and behaviour change.

As set out in our 10-Year Health Plan for England, we are taking decisive action on the obesity crisis, including restricting junk food advertising to children, and setting healthy sales reporting and targets for large food businesses.

Whilst we recognise that prevention will always be better than a cure, we also need to support those already living with obesity. We have committed to doubling the number of people able to access the NHS Digital Weight Management Programme and to expand access to the newest obesity medicines.

Commercial access agreements, including confidential discounts, are negotiated to secure affordability and value for money for the National Health Service, and to enable access to clinically effective treatments that may not otherwise meet cost effectiveness thresholds at list price. As is standard across NHS medicines commissioning, the specific terms of commercial agreements remain confidential to protect the NHS’s negotiating position and to ensure best value for public funds.

NHS England, alongside the Department and the National Institute for Health and Care Excellence, routinely engages with pharmaceutical companies, including Novo Nordisk and Eli Lilly, through standard market access and appraisal processes, and commercial and supply discussions following NICE recommendations, and ongoing dialogue on implementation, demand management, and system readiness. NHS England does not comment publicly on the detail of individual commercial negotiations.

For weight management medicines, NHS England is supporting implementation via a phased and prioritised rollout approach. Prioritising populations with the greatest clinical need aligns with NHS objectives to reduce health inequalities.

NHS England is working with regions and integrated care boards to support consistent implementation of national policy, and to address unwarranted variation through guidance, oversight, and data monitoring. These approaches are designed to ensure that cost pressures do not drive postcode-based inequities, while enabling the safe and sustainable introduction of new treatments at scale.

Commercial access agreements, including confidential discounts, are negotiated to secure affordability and value for money for the National Health Service, and to enable access to clinically effective treatments that may not otherwise meet cost effectiveness thresholds at list price. As is standard across NHS medicines commissioning, the specific terms of commercial agreements remain confidential to protect the NHS’s negotiating position and to ensure best value for public funds.

NHS England, alongside the Department and the National Institute for Health and Care Excellence, routinely engages with pharmaceutical companies, including Novo Nordisk and Eli Lilly, through standard market access and appraisal processes, and commercial and supply discussions following NICE recommendations, and ongoing dialogue on implementation, demand management, and system readiness. NHS England does not comment publicly on the detail of individual commercial negotiations.

For weight management medicines, NHS England is supporting implementation via a phased and prioritised rollout approach. Prioritising populations with the greatest clinical need aligns with NHS objectives to reduce health inequalities.

NHS England is working with regions and integrated care boards to support consistent implementation of national policy, and to address unwarranted variation through guidance, oversight, and data monitoring. These approaches are designed to ensure that cost pressures do not drive postcode-based inequities, while enabling the safe and sustainable introduction of new treatments at scale.

We have reached a landmark agreement with the United States of America that secures a preferential tariff rate of 0% for all pharmaceuticals exports to the US for at least three years, and preferential terms for the United Kingdom’s medical technology exports, meaning no additional new tariffs on medical technology. This means that, unlike anywhere else in the world, life sciences companies exporting medicines from the UK to the US will face no tariffs to do so, protecting jobs and investment in the UK.

The agreement will see the National Health Service invest approximately 25% more in innovative treatments which will be achieved through an increase to the standard cost-effectiveness threshold that the National Institute for Health and Care Excellence (NICE) uses and a change to the way in which NICE values health benefits to better reflect societal preferences.

There are currently no plans to increase the cost‑effectiveness threshold for the highly specialised technologies (HST) programme. The HST programme already operates at a much higher threshold than standard NICE technology appraisals, reflecting the challenges of bringing treatments for very rare conditions to market, and NICE has been able to recommend nearly all the treatments that have been evaluated through the HST programme for NHS use.

We have reached a landmark agreement with the United States of America that secures a preferential tariff rate of 0% for all pharmaceuticals exports to the US for at least three years, and preferential terms for the United Kingdom’s medical technology exports, meaning no additional new tariffs on medical technology. This means that, unlike anywhere else in the world, life sciences companies exporting medicines from the UK to the US will face no tariffs to do so, protecting jobs and investment in the UK.

The agreement will see the National Health Service invest approximately 25% more in innovative treatments which will be achieved through an increase to the standard cost-effectiveness threshold that the National Institute for Health and Care Excellence (NICE) uses and a change to the way in which NICE values health benefits to better reflect societal preferences.

There are currently no plans to increase the cost‑effectiveness threshold for the highly specialised technologies (HST) programme. The HST programme already operates at a much higher threshold than standard NICE technology appraisals, reflecting the challenges of bringing treatments for very rare conditions to market, and NICE has been able to recommend nearly all the treatments that have been evaluated through the HST programme for NHS use.

Integrated care boards currently have a statutory duty in relation to public involvement and consultation and are subject to an annual assessment by NHS England of their functions.

The abolition of Healthwatch England and Local HealthWatch arrangements will require primary legislation and is subject to the will of Parliament.

We have reached a landmark agreement with the United States of America that secures a preferential tariff rate of 0% for all pharmaceuticals exports to the US for at least three years, and preferential terms for the United Kingdom’s medical technology exports, meaning no additional new tariffs on medical technology. This means that, unlike anywhere else in the world, life sciences companies exporting medicines from the UK to the US will face no tariffs to do so, protecting jobs and investment in the UK.

The agreement will see the National Health Service invest approximately 25% more in innovative treatments which will be achieved through an increase to the standard cost-effectiveness threshold that the National Institute for Health and Care Excellence (NICE) uses and a change to the way in which NICE values health benefits to better reflect societal preferences.

There are currently no plans to increase the cost‑effectiveness threshold for the highly specialised technologies (HST) programme. The HST programme already operates at a much higher threshold than standard NICE technology appraisals, reflecting the challenges of bringing treatments for very rare conditions to market, and NICE has been able to recommend nearly all the treatments that have been evaluated through the HST programme for NHS use.

The Government has accepted the recommendations of Dr Penny Dash’s Review of patient safety across the health and care landscape and confirmed in its 10-Year Health Plan for England that the strategic functions of Healthwatch England will transfer to a new patient experience directorate within the Department. This change is intended to strengthen the role of patient voice by embedding it at the centre of a reformed Department.

The Department continues to engage with Healthwatch England as this work progresses. Discussions with Healthwatch England have not included the making of public comments about the transfer of Healthwatch England functions to the proposed patient experience directorate.

The Government has accepted the Dash review recommendations and will abolish Healthwatch England and Local Healthwatch (LHW) in their current form.

We are proposing to place responsibility for the health function of LHW with integrated care boards (ICBs). ICBs will ensure the functions are incorporated in provider organisations alongside existing patient engagement work such as Patient Participation Groups. Local authorities will be responsible for the social care LHW functions.

However, the abolition of Healthwatch England and LHW arrangements will require primary legislation and is subject to the will of Parliament. Details of how any proposed changes will impact ICBs will be developed in due course.

The Government has accepted the Dash review recommendations and will abolish Healthwatch England and Local Healthwatch (LHW) in their current form.

We are proposing to place responsibility for the health function of LHW with integrated care boards (ICBs). ICBs will ensure the functions are incorporated in provider organisations alongside existing patient engagement work such as Patient Participation Groups. Local authorities will be responsible for the social care LHW functions.

However, the abolition of Healthwatch England and LHW arrangements will require primary legislation and is subject to the will of Parliament. Details of how any proposed changes will impact ICBs will be developed in due course.

The Government has accepted the Dash review recommendations and will abolish Healthwatch England and Local Healthwatch (LHW) in their current form.

We are proposing to place responsibility for the health function of LHW with integrated care boards (ICBs). ICBs will ensure the functions are incorporated in provider organisations alongside existing patient engagement work such as Patient Participation Groups. Local authorities will be responsible for the social care LHW functions.

However, the abolition of Healthwatch England and LHW arrangements will require primary legislation and is subject to the will of Parliament. Details of how any proposed changes will impact ICBs will be developed in due course.

As set out in the Dash Report and the 10-Year Health Plan for England, the strategic functions of Healthwatch England will transfer to a new directorate for patient experience within the Department.

We are committed to ensuring that the patient voice is not only heard but embedded at the highest levels of our leadership and decision-making structures. By creating clear routes for patient insight, feedback, and lived experience to directly influence senior leaders at the national level, we will ensure that policies, strategic priorities, and service design will be shaped by what matters most to the people who use health services.

The Care Quality Commission (CQC) currently gathers views through the Give Feedback on Care section on the CQC website, which allows people who use services or staff to submit experiences or concerns about a service.

The feedback gathered helps to shape the CQC’s regulatory activity and allows them to identify issues and themes in the quality of care. During their inspections, the CQC will consider information from a variety of sources, which includes feedback received from members of the public regarding their experience of a service, or the experience of someone they represent.

We are not proposing to change this as part of the implementation of the recommendations in the report on the review of patient safety across the health and care landscape.

The performance of the NHS Genomic Medicine Service is monitored quarterly through an assurance framework, which ensures all seven NHS Genomic Laboratory Hubs are operating to national quality standards. This identifies and minimises any potential variation and ensures consistent delivery of the criteria outlined in the National Genomic Test Directory.

The National Institute for Health and Care Excellence (NICE) is the independent body that makes evidence-based recommendations for the National Health Service on whether new medicines should be routinely funded by the NHS on the basis of an assessment of clinical and cost effectiveness. NICE develops its guidance through extensive engagement with interested parties, including patient groups.

NICE is currently evaluating vorasidenib for treating astrocytoma or oligodendroglioma with IDH1 or IDH2 mutations after surgery in people 12 years old and over. As part of the appraisal process, NICE’s independent committee was provided with evidence submissions from three patient groups. The committee also heard expert personal perspectives from two patient experts.

The draft guidance was shared with all stakeholders as well as being published on the NICE website for public comment as part of the consultation which took place between 15 October and 4 November 2025. The committee reviewed the consultation comments at the committee meeting on 20 November 2025. NICE currently expects to publish final guidance in January 2026.

The Department delivers research via the National Institute for Health and Care Research (NIHR) and is committed to furthering our investment and driving scientific advancements in research into the causes and treatment of brain tumours. Between 2018/19 and 2023/24, the NIHR invested £11.8 million, and UK Research and Innovation invested £46.8 million in this area.

During the same period, the NIHR’s wider investments of approximately £37.5 million in research infrastructure and the research workforce have enabled the delivery of an additional 261 brain tumour research studies, allowing over 11,400 more people to participate in brain tumour research. NIHR infrastructure provides world-class research expertise, specialist facilities, a research delivery workforce, and support services to enable and deliver research across the National Health Service and wider health and care system.

In September 2024 the NIHR launched a package of support to deliver a step-change in brain cancer research by establishing a national NIHR Brain Tumour Research Consortium to bring together researchers from different disciplines to drive scientific advancements in how to prevent, detect, manage, and treat brain tumours. We will announce funding decisions this year, including a dedicated funding call for research into care, support, and rehabilitation for people living with brain tumours, as well as the Allied Health Professionals Brain Tumour Research Fellowship programme, a partnership with the Tessa Jowell Brain Cancer Mission.

These funding calls mark an innovative collaboration between charities, research funders, and the Government to listen and consult with the brain tumour community to increase and accelerate research into brain tumours. The NIHR continues to welcome funding applications for research into any aspect of human health and care, including brain tumours.

To improve clinical trial access for brain tumour patients, the 10-Year Health Plan outlines how the Department will fast-track clinical trial set-up time to 150 days by March 2026. We are building capacity to deliver clinical trials through 21 new Commercial Research Delivery Centres across the United Kingdom, and we also support the Rare Cancers Private Members Bill. Once implemented, this bill will make it easier for brain tumour patients to be recruited to clinical trials.

Additionally, the National Cancer Plan will include further details on how we will improve outcomes for cancer patients, as well as speeding up diagnosis and treatment, ensuring patients have access to the latest treatments and technology, including access to genetic testing to support treatment.